Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Related financial report
RXRX similar filings
- 24 Jun 24 Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Its Download Day
- 7 Jun 24 Submission of Matters to a Vote of Security Holders
- 24 May 24 Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
- 9 May 24 Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
- 16 Apr 24 Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
- 27 Feb 24 Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
- 7 Feb 24 Departure of Directors or Certain Officers
Filing view
External links
Exhibit 16.1
May 9, 2024
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Commissioners:
We have read Item 4.01 of Form 8-K dated May 9, 2024, of Recursion Pharmaceuticals, Inc. and are in agreement with the statements contained in the first, fourth, fifth, sixth and seventh paragraphs and the second sentence of the second paragraph on pages two and three therein. We have no basis to agree or disagree with other statements of the registrant contained therein.
/s/ Ernst & Young LLP